Meditor Group Ltd - Q4 2022 holdings

$148 Million is the total value of Meditor Group Ltd's 4 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was - .

 Value Shares↓ Weighting
No holdings reported for quarter Q4 2022
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-01-05
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
EXELIXIS INC43Q4 202388.9%
ALKERMES PLC31Q4 202062.6%
ISHARES MSCI INDIA ETF31Q4 20235.5%
WISDOMTREE INDIA EARNINGS FUND31Q4 20235.5%
ESPERION THERAPEUTICS INC27Q4 202334.4%
VIVUS INC15Q4 201621.3%
CELLDEX THERAPEUTICS14Q2 20202.7%
PROSHARES ULTRAPRO SHORT S&P5004Q4 20173.8%
PROSHARES ULTRASHORT S&P5004Q4 20173.0%
PROSHARES ULTRASHORT S&P 500 ETF3Q3 20190.8%

View Meditor Group Ltd's complete holdings history.

Latest significant ownerships (13-D/G)
Meditor Group Ltd Q4 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
EXELIXIS, INC.April 09, 201915,001,0735.0%
VIVUS INCDecember 19, 20125,002,8965.0%
VIVUS INCMarch 21, 20126,177,5006.3%
VION PHARMACEUTICALS INCFebruary 15, 20085,736,2007.6%
CYPRESS BIOSCIENCE INCSeptember 26, 20071,864,6455.0%
ONYX PHARMACEUTICALS INCSeptember 12, 20072,627,8004.8%
ACUSPHERE INCJuly 26, 20071,839,4214.0%
NOVACEA INCJune 11, 2007800,0003.4%
ATHEROGENICS INCMay 02, 20071,361,8003.5%

View Meditor Group Ltd's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-01-04
SC 13G/A2024-01-03
13F-HR2023-10-31
13F-HR2023-07-25
13F-HR2023-04-10
13F-HR2023-01-05
SC 13G/A2023-01-04
13F-HR2022-11-07
13F-HR2022-07-18
13F-HR2022-04-12

View Meditor Group Ltd's complete filings history.

Compare quarters

Export Meditor Group Ltd's holdings